Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Pramand LLC currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are divided between 2 distinct examiners and 2 distinct art units. GHALI, ISIS A D is the busiest examiner, handling 1 pending office action. The distribution of cases across different examiners and art units suggests that the company is pursuing multiple distinct technical paths within its current patent portfolio.
With 2 pending office actions split between 2 distinct examiners, the company avoids the risks associated with a single point of failure in its prosecution strategy. However, the use of 2 distinct art units means that the practitioner must navigate two different sets of administrative guidelines and potentially different examination cultures. This requires a more nuanced strategy than a centralized portfolio. Practitioners should ensure that the arguments made to GHALI, ISIS A D are consistent with those presented to the other examiner to maintain a cohesive claim set across the 2 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GHALI, ISIS A D | 1 | 27.9% | +41.6% |
| KOO, BENJAMIN K | 1 | 57.1% | +49.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17494752 | TRANSCERVICAL ACCESS SYSTEMS FOR INTRAUTERINE FLUID EXCHANGE, SUCH AS PLACEMENT OF HYDROGELS FORMED IN SITU | KOO, BENJAMIN K | 42d overdue |
| 18142956 | WATER ACTIVATED HYDROGEL-BASED MEDICAL PATCHES, FLEXIBLE SUBSTRATES AND METHODS OF MAKING AND USING SUCH PATCHES | GHALI, ISIS A D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17494752 | TRANSCERVICAL ACCESS SYSTEMS FOR INTRAUTERINE FLUID EXCHANGE, SUCH AS PLACEMENT OF HYDROGELS FORMED IN SITU | KOO, BENJAMIN K | 42d overdue |
| 18142956 | WATER ACTIVATED HYDROGEL-BASED MEDICAL PATCHES, FLEXIBLE SUBSTRATES AND METHODS OF MAKING AND USING SUCH PATCHES | GHALI, ISIS A D | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| 3783 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18142956 | WATER ACTIVATED HYDROGEL-BASED MEDICAL PATCHES, FLEXIBLE SUBSTRATES AND METHODS OF MAKING AND USING SUCH PATCHES | GHALI, ISIS A D | 1611 | §103§112 | Non-Final OA | — | Pending | May 03, 2023 |
| 17494752 | TRANSCERVICAL ACCESS SYSTEMS FOR INTRAUTERINE FLUID EXCHANGE, SUCH AS PLACEMENT OF HYDROGELS FORMED IN SITU | KOO, BENJAMIN K | 3783 | §102§103§112 | Non-Final OA | 42d overdue | Pending | Oct 05, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial